Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25

呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25

基本信息

  • 批准号:
    7903722
  • 负责人:
  • 金额:
    $ 35.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-02 至 2010-08-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT. Our overall goal is to identify novel components of the host innate antiviral response and novel mechanisms by which viruses subvert this response to cause disease. Cardiac myocytes are non-replenishable; thus the heart is unusually dependent on this first-line defense. Indeed, we have shown that the cardiac Type I interferon (IFN) response is unique, and that in reovirus-induced murine myocarditis the IFN response differs between virus strains and is critical for protection. We continue to use this powerful tool-kit of viruses to probe the innate response in a highly vulnerable organ, the heart, and have made two new discoveries. First, we found that reovirus inhibits IFN signaling by a mechanism not previously shown for any virus. Specifically, reovirus protein ¿2 represses IFN signaling, and repression is virus strain-specific and is associated with unusual nuclear accumulation of transcription factor IRF9, likely reflecting concomitant interference with its normal participation in induction of IFN- stimulated genes. We hypothesize that reovirus protein ¿2 modulates IRF9 structure / function to inhibit IFN signaling, and that ¿2 repression of IFN signaling in cardiac cells is required for myocarditis. In Specific Aim 1, we will: i) determine whether ¿2 alters IRF9 structure or cellular binding partners; ii) identify ¿2 and IRF9 domains required for IRF9 effects, and iii) determine whether ¿2 modulation of IRF9 is required for reovirus-induced myocarditis. Second, using a proteomic discovery approach, we identified a new IFN-independent protective response which can be subverted by virus. We found that reoviruses induce phosphorylation (non- myocarditic reovirus) or degradation (myocarditic reovirus) of Heat Shock Protein-25 (HSP25) in cardiac myocytes, and that this is cell type-specific and IFN-independent. Members of seven virus families induce HSP25 expression or phosphorylation but not degradation, yet only one study has addressed HSP25 antiviral effects. Many cardiac insults induce HSP25 phosphorylation but not degradation, and over-expressed HSP25 protects against stress- induced cardiac damage. We hypothesize that HSP25 plays a cell type-specific antiviral role, that phosphorylated HSP25 is antiviral, and that viruses have evolved mechanisms to evade this innate response. In Specific Aim 2, we will determine: i) cell type-specificity for reovirus alteration of HSP25, ii) mechanisms by which reovirus alters HSP25, and iii) mechanisms by which HSP25 inhibits reovirus infection. The broader impact of our studies is to increase the catalog of protective host factors that can be sabotaged by viruses, potentially providing new therapeutic targets, particularly for viral myocarditis which remains an intractable disease.
摘要。我们的总体目标是确定宿主先天性抗病毒药物的新成分, 病毒破坏这种反应而导致疾病的新机制。 心肌细胞是不可补充的;因此心脏异常依赖于这一线细胞 防御事实上,我们已经证明,心脏I型干扰素(IFN)反应是独特的, 在呼肠孤病毒诱导的小鼠心肌炎中,不同病毒株的IFN应答不同 并且对于保护至关重要。我们继续使用这种强大的病毒工具包来探测 在一个非常脆弱的器官,心脏的先天反应,并取得了两个新的发现。 首先,我们发现呼肠孤病毒通过一种以前没有发现的机制抑制IFN信号传导 任何病毒。具体地说,呼肠孤病毒蛋白质2抑制IFN信号传导,并且抑制是病毒 菌株特异性,并与转录因子IRF 9的异常核积累有关, 这可能反映了伴随干扰其正常参与IFN-γ的诱导。 刺激基因我们假设呼肠孤病毒蛋白质2调节IRF 9的结构/功能 抑制IFN信号传导,心肌细胞中IFN信号传导的抑制是 心肌炎在具体目标1中,我们将:i)确定2是否改变IRF 9结构或细胞 结合伴侣; ii)鉴定IRF 9效应所需的IRF 2和IRF 9结构域,和iii)确定 呼肠孤病毒诱导的心肌炎是否需要IRF 9的调节。第二,使用 通过蛋白质组学发现方法,我们发现了一种新的IFN-依赖性保护反应, 而这些都可以被病毒破坏。我们发现呼肠孤病毒诱导磷酸化(非- 心肌呼肠孤病毒)或热休克蛋白-25(HSP 25)降解(心肌呼肠孤病毒)。 心肌细胞,这是细胞类型特异性和干扰素无关。成员七人 病毒家族诱导HSP 25表达或磷酸化,但不降解,但只有一种 研究已经解决了HSP 25的抗病毒作用。许多心脏损伤诱导HSP 25 磷酸化而不是降解,过表达的HSP 25可以保护机体免受应激。 导致心脏损伤。我们假设HSP 25发挥细胞类型特异性抗病毒作用, 磷酸化的HSP 25是抗病毒的,病毒已经进化出了逃避病毒的机制, 这种与生俱来的反应在具体目标2中,我们将确定:i)呼肠孤病毒的细胞类型特异性 ii)呼肠孤病毒改变HSP 25的机制,和iii)HSP 25的改变机制, 其中HSP 25抑制呼肠孤病毒感染。我们的研究的更广泛的影响是增加 一系列可以被病毒破坏的保护性宿主因子,可能提供新的 治疗靶点,特别是对于仍然是难治性疾病的病毒性心肌炎。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARBARA SHERRY其他文献

BARBARA SHERRY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARBARA SHERRY', 18)}}的其他基金

Reovirus modulation of the cardiac innate response: Type I interferon and HSP25
呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25
  • 批准号:
    8644636
  • 财政年份:
    2013
  • 资助金额:
    $ 35.88万
  • 项目类别:
Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25
呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25
  • 批准号:
    8583298
  • 财政年份:
    2010
  • 资助金额:
    $ 35.88万
  • 项目类别:
Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25
呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25
  • 批准号:
    8771414
  • 财政年份:
    2010
  • 资助金额:
    $ 35.88万
  • 项目类别:
Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25
呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25
  • 批准号:
    8041990
  • 财政年份:
    2010
  • 资助金额:
    $ 35.88万
  • 项目类别:
REGULATION OF CHEMOKINE RECEPTOR EXPRESSION DURING SEPSIS
脓毒症期间趋化因子受体表达的调节
  • 批准号:
    8167223
  • 财政年份:
    2010
  • 资助金额:
    $ 35.88万
  • 项目类别:
Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25
呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25
  • 批准号:
    8389664
  • 财政年份:
    2010
  • 资助金额:
    $ 35.88万
  • 项目类别:
Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25
呼肠孤病毒对心脏先天反应的调节:I 型干扰素和 HSP25
  • 批准号:
    8197483
  • 财政年份:
    2010
  • 资助金额:
    $ 35.88万
  • 项目类别:
REGULATION OF CHEMOKINE RECEPTOR EXPRESSION DURING SEPSIS
脓毒症期间趋化因子受体表达的调节
  • 批准号:
    7951918
  • 财政年份:
    2009
  • 资助金额:
    $ 35.88万
  • 项目类别:
REGULATION OF CHEMOKINE RECEPTOR EXPRESSION DURING SEPSIS SURVIVORS
脓毒症幸存者期间趋化因子受体表达的调节
  • 批准号:
    7719268
  • 财政年份:
    2008
  • 资助金额:
    $ 35.88万
  • 项目类别:
The cardiac interferon response to reovirus infection
心脏干扰素对呼肠孤病毒感染的反应
  • 批准号:
    7056053
  • 财政年份:
    2004
  • 资助金额:
    $ 35.88万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 35.88万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 35.88万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 35.88万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 35.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了